{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:40:01Z","timestamp":1786372801400,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,11]]},"abstract":"\n Background and objectives<\/jats:title>\n In the treatment of CKD, individual patients show a wide variation in their response to many drugs, including renin-angiotensin-aldosterone system inhibitors (RAASi). To investigate whether therapy resistance to RAASi can be overcome by uptitrating the dose of drug, changing the mode of intervention (with drugs from similar or different classes), or lowering dietary sodium intake, we meta-analyzed individual responses to different modes of interventions.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n \n Randomized crossover trials were analyzed to assess correlation of individual responses to RAASi and nonsteroidal anti-inflammatory drugs (NSAIDs;\n n<\/jats:italic>\n =395 patients). Included studies compared the antialbuminuric effect of uptitrating the dose of RAASi (\n n<\/jats:italic>\n =10 studies) and NSAIDs (\n n<\/jats:italic>\n =1), changing within the same class of RAASi (\n e.g.<\/jats:italic>\n , angiotensin-converting enzyme inhibition to angiotensin receptor blockers;\n n<\/jats:italic>\n =5) or NSAIDs (\n n<\/jats:italic>\n =1), changing from RAASi to NSAIDs (\n n<\/jats:italic>\n =2), and changing from high to low sodium intake (\n n<\/jats:italic>\n =5). A two-stage meta-analysis was conducted: Deming regression was conducted in each study to assess correlations in response, and individual study results were then meta-analyzed.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The albuminuria response to one dose of RAASi or NSAIDs positively correlated with the response to a higher dose of the same drug (\n r<\/jats:italic>\n =0.72; 95% confidence interval [95% CI], 0.66 to 0.78), changes within the same class of RAASi or NSAIDs (\n r<\/jats:italic>\n =0.54; 95% CI, 0.35 to 0.68), changes between RAASi and NSAIDs (\n r<\/jats:italic>\n =0.44; 95% CI, 0.16 to 0.66), and changes from high to moderately low salt intake (\n r<\/jats:italic>\n =0.36; 95% CI, 0.22 to 0.48). Results were similar when the individual systolic BP and potassium responses were analyzed, and were consistent in patients with and without diabetes.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Individuals who show a poor response to one dose or type of RAASi also show a poor response to higher doses, other types of RAASi or NSAIDs, or a reduction in dietary salt intake. Whether other drugs or drug combinations targeting pathways beyond the renin-angiotensin-aldosterone system and prostaglandins would improve the individual poor response requires further study.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.00390117","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T20:40:32Z","timestamp":1507754432000},"page":"1804-1813","source":"Crossref","is-referenced-by-count":6,"title":["Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention"],"prefix":"10.2215","volume":"12","author":[{"given":"Sergei I.","family":"Petrykiv","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozewijn Dirk","family":"Laverman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, ZiekenhuisGroep Twente, Almelo, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Persson","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, Steno Diabetes Center, Gentofte, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liffert","family":"Vogt","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, Steno Diabetes Center, Gentofte, Denmark;"},{"name":"The Novo Nordisk Foundation Center for Basic and Metabolic Research, University of Copenhagen, Copenhagen, Denmark; and"},{"name":"Faculty of Health, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"de Borst","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald T.","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09339","article-title":"Translating cancer research into targeted therapeutics.","volume":"467","author":"de Bono","year":"2010","journal-title":"Nature"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.kint.2016.02.009","article-title":"Precision medicine comes of age in nephrology: Identification of novel biomarkers and therapeutic targets for chronic kidney disease.","volume":"89","author":"Wyatt","year":"2016","journal-title":"Kidney Int"},{"issue":"Suppl 4","key":"B3-20230813","doi-asserted-by":"crossref","first-page":"iv105","DOI":"10.1093\/ndt\/gfv210","article-title":"Drugs meeting the molecular basis of diabetic kidney disease: Bridging from molecular mechanism to personalized medicine.","volume":"30","author":"Lambers Heerspink","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: A post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/eurheartj\/ehr017","article-title":"Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials.","volume":"32","author":"Holtkamp","year":"2011","journal-title":"Eur Heart J"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5414\/CNP63181","article-title":"Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: Results of the HOPE study.","volume":"63","author":"Mann","year":"2005","journal-title":"Clin Nephrol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1681\/ASN.2008040416","article-title":"Supramaximal dose of candesartan in proteinuric renal disease.","volume":"20","author":"Burgess","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney Int"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(14)70030-0","article-title":"Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: A randomised clinical trial.","volume":"2","author":"Kwakernaak","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/jraas.2001.004","article-title":"Discordant responses to two classes of drugs acting on the renin-angiotensin system.","volume":"2","author":"Sever","year":"2001","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1046\/j.1523-1755.2000.07506.x","article-title":"Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.","volume":"75","author":"Bos","year":"2000","journal-title":"Kidney Int Suppl"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ki.1994.113","article-title":"Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?","volume":"45","author":"Gansevoort","year":"1994","journal-title":"Kidney Int"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","article-title":"Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.","volume":"57","author":"Andersen","year":"2000","journal-title":"Kidney Int"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/ndt\/gfn644","article-title":"Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.","volume":"24","author":"Vogt","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s00125-010-1789-6","article-title":"Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: A randomised crossover trial.","volume":"53","author":"Persson","year":"2010","journal-title":"Diabetologia"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00125-008-1184-8","article-title":"Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: A randomised crossover trial.","volume":"52","author":"Schjoedt","year":"2009","journal-title":"Diabetologia"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","article-title":"Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.","volume":"32","author":"Persson","year":"2009","journal-title":"Diabetes Care"},{"key":"B20-20230813","first-page":"244","article-title":"Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria.","volume":"9","author":"Gansevoort","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"d4366","DOI":"10.1136\/bmj.d4366","article-title":"Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: Randomised controlled trial.","volume":"343","author":"Slagman","year":"2011","journal-title":"BMJ"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1681\/ASN.2016040407","article-title":"Holland Nephrology Study (HONEST) Network","volume":"28","author":"Keyzer","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2337\/diacare.10.4.428","article-title":"Renal excretion of prostaglandin E2 and plasma renin activity in type I diabetes mellitus: Relationship to normoglycemia achieved with artificial pancreas.","volume":"10","author":"Esmatjes","year":"1987","journal-title":"Diabetes Care"},{"key":"B24-20230813","first-page":"989","article-title":"The role of urinary PGE2 and renin-angiotensin-aldosterone system in the pathogenesis of essential hypertension.","volume":"4","author":"Ruilope","year":"1982","journal-title":"Clin Exp Hypertens A"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ndt\/13.7.1682","article-title":"The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.","volume":"13","author":"Buter","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2215\/CJN.13651215","article-title":"Defining glomerular disease in mechanistic terms: Implementing an integrative biology approach in nephrology.","volume":"11","author":"Mariani","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12967-016-0960-3","article-title":"Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.","volume":"14","author":"Pena","year":"2016","journal-title":"J Transl Med"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s00125-016-4001-9","article-title":"Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease.","volume":"59","author":"Pena","year":"2016","journal-title":"Diabetologia"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bcp.12655","article-title":"The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.","volume":"80","author":"Schievink","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jdiacomp.2016.09.016","article-title":"Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.","volume":"31","author":"Zobel","year":"2017","journal-title":"J Diabetes Complications"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial.","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0895-7061(01)01307-3","article-title":"Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism?","volume":"14","author":"Stergiou","year":"2001","journal-title":"Am J Hypertens"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(98)07614-4","article-title":"Optimisation of antihypertensive treatment by crossover rotation of four major classes.","volume":"353","author":"Dickerson","year":"1999","journal-title":"Lancet"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201711000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:19Z","timestamp":1786369039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201711000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.00390117","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,11]]}}}